Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Access & Reimbursement

Set Alert for Market Access & Reimbursement

Latest From Market Access

Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation

Draft version of order signals a focus on insurance benefit design, accelerating drug approvals and de-regulation.

Pricing Debate Market Access

Best Of BIO: Policy & Regulatory Updates From BIO 2017

Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.

ImmunoOncology Market Access

Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?

Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.

Canada United States

Support For Continued EU Co-operation On Health Technology Assessment Is ‘Overwhelming’

Support is strong for continuing EU co-ordination on health technology assessment, according to a report on the responses to a consultation on the topic. An impact assessment on what will follow the EUnetHTA Joint Action 3 will come in late 2017.

BioPharmaceutical Europe

Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback

As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.

Pricing Debate Market Access

First Benelux Joint Pricing and Reimbursement Pilot Fails Over Vertex’ Orkambi

The first pilot for the Benelux joint pricing and reimbursement process has failed. Negotiations between Vertex and the ministries of health in Belgium and the Netherlands have ended with no agreement on price for cystic fibrosis drug Orkambi.

Europe BioPharmaceutical
See All
UsernamePublicRestriction

Register